Guggenheim initiated coverage of Twist Bioscience with a Buy rating and $53 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $48 from $43 at Scotiabank
- Evercore ISI removes several healthcare names from ‘Tactical Outperform’ list
- Twist Bioscience price target raised to $28 from $25 at JPMorgan
- Twist Bioscience price target raised to $55 from $48 at TD Cowen
- Twist Bioscience price target raised to $40 from $39 at Baird
Questions or Comments about the article? Write to editor@tipranks.com